2025年度神经内分泌肿瘤药物治疗研究进展OA

The incidence of neuroendocrine neoplasms(NENs)continues to rise.Based on pathological differentiation,they are classified into well-differentiated neuroendocrine tumor(NET)and poorly-differentiated neuroendocrine carcinoma(NEC).In 2025,significant progress was made in the treatment of advanced NET,with multiple phase Ⅲ clinical trial results published,particularly notable advances in the field of radionuclide therapy.Two studies of peptide receptor radionuclide therapy from China demonstrated the efficacy of this approach in Chinese NET patients.A Japanese study on everolimus combined with lanreotide as first-line therapy for gastro-entero-pancreatic NETs suggested improved efficacy with combination therapy.Although phase Ⅲ data remain lacking in 2025 for treating advanced NEC,several phase Ⅰ/Ⅱ trials of novel immunotherapies showed promising results.This article reviews and summarizes the advances in medical treatments for NENs during 2025.